DE69837764T2 - Rhabdovirus mit gentechnisch veränderter hülle - Google Patents
Rhabdovirus mit gentechnisch veränderter hülle Download PDFInfo
- Publication number
- DE69837764T2 DE69837764T2 DE69837764T DE69837764T DE69837764T2 DE 69837764 T2 DE69837764 T2 DE 69837764T2 DE 69837764 T DE69837764 T DE 69837764T DE 69837764 T DE69837764 T DE 69837764T DE 69837764 T2 DE69837764 T2 DE 69837764T2
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- virus
- cells
- vsv
- infected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 claims abstract description 112
- 241000711975 Vesicular stomatitis virus Species 0.000 claims abstract description 110
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 19
- 102000005962 receptors Human genes 0.000 claims abstract description 18
- 108020003175 receptors Proteins 0.000 claims abstract description 18
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 108010083930 HIV Receptors Proteins 0.000 claims abstract description 6
- 102000006481 HIV Receptors Human genes 0.000 claims abstract description 6
- 210000004779 membrane envelope Anatomy 0.000 claims abstract description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 61
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 55
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 24
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 101150082239 G gene Proteins 0.000 claims description 8
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 8
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108050001488 Rhabdovirus glycoproteins Proteins 0.000 claims 1
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 171
- 108090000288 Glycoproteins Proteins 0.000 abstract description 11
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 8
- 102000003886 Glycoproteins Human genes 0.000 abstract description 7
- 230000002950 deficient Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 5
- 230000003362 replicative effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 61
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 35
- 239000002245 particle Substances 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108091006027 G proteins Proteins 0.000 description 22
- 108091000058 GTP-Binding Proteins 0.000 description 22
- 102100034349 Integrase Human genes 0.000 description 21
- 102000030782 GTP binding Human genes 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 16
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 15
- 230000002458 infectious effect Effects 0.000 description 15
- 101710141454 Nucleoprotein Proteins 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000010820 immunofluorescence microscopy Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101710091045 Envelope protein Proteins 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000035784 germination Effects 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 5
- 108010046722 Thrombospondin 1 Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010042566 Superinfection Diseases 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 2
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 101150075764 CD4 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710126503 Envelope glycoprotein G Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001123862 Mico Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001094044 Mus musculus Solute carrier family 26 member 6 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006658 host protein synthesis Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
- C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Confectionery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5236697P | 1997-07-11 | 1997-07-11 | |
| US52366P | 1997-07-11 | ||
| PCT/US1998/014527 WO1999002657A1 (en) | 1997-07-11 | 1998-07-10 | Rhabdoviruses with reengineered coats |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69837764D1 DE69837764D1 (de) | 2007-06-21 |
| DE69837764T2 true DE69837764T2 (de) | 2008-01-31 |
Family
ID=21977148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69837764T Expired - Lifetime DE69837764T2 (de) | 1997-07-11 | 1998-07-10 | Rhabdovirus mit gentechnisch veränderter hülle |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1012244B1 (https=) |
| JP (1) | JP4434478B2 (https=) |
| AT (1) | ATE361973T1 (https=) |
| AU (1) | AU731663B2 (https=) |
| CA (1) | CA2295858C (https=) |
| DE (1) | DE69837764T2 (https=) |
| DK (1) | DK1012244T3 (https=) |
| ES (1) | ES2287977T3 (https=) |
| PT (1) | PT1012244E (https=) |
| WO (1) | WO1999002657A1 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485440B2 (en) | 1995-09-27 | 2009-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
| WO1998002530A1 (en) | 1996-07-15 | 1998-01-22 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| US7632508B2 (en) | 1997-05-23 | 2009-12-15 | The United States Of America | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| US7951383B2 (en) | 1997-05-23 | 2011-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuated parainfluenza virus (PIV) vaccines |
| US7314631B1 (en) | 1997-05-23 | 2008-01-01 | The United States Of America As Represented By The Department Of Health And Human Services | Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV) |
| US7208161B1 (en) | 1997-05-23 | 2007-04-24 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
| US7201907B1 (en) | 1997-05-23 | 2007-04-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines |
| US20030082209A1 (en) | 2000-07-05 | 2003-05-01 | Skiadopoulos Mario H. | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| US7250171B1 (en) | 1997-05-23 | 2007-07-31 | United States Of America As Represented By The Dept. Of Health & Human Services | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein |
| JP4837827B2 (ja) | 1998-06-12 | 2011-12-14 | マウント シナイ スクール オブ メディシン | 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基 |
| DE69937999T2 (de) | 1998-06-12 | 2009-01-29 | Avir Green Hills Biotechnology Research Development Trade Ag | Interferon induzierende genetisch veränderte attenuierte viren |
| US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| ATE419369T1 (de) | 1999-07-09 | 2009-01-15 | Us Gov Health & Human Serv | Chimäre mensch-rinder respiratory syncytial virus vakzinen |
| IL148621A0 (en) * | 1999-09-17 | 2002-09-12 | Pro Virus Inc | Oncolytic virus |
| US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
| EP1130089A1 (en) * | 2000-02-17 | 2001-09-05 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| WO2001077394A1 (en) | 2000-04-10 | 2001-10-18 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
| KR20040002853A (ko) | 2001-01-19 | 2004-01-07 | 비로노바티브 비.브이. | 감응성 포유류에서 호흡계 질환을 유발하는 바이러스 |
| US8715922B2 (en) | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| EP1485468A4 (en) | 2002-02-21 | 2007-01-03 | Medimmune Vaccines Inc | RECOMBINANT PARAIN FLUENZAVIRUS EXPRESSION SYSTEMS AND VACCINES WITH ANTIGENS FROM METAPNEUMOVIRUS STEM-RELATED HETEROLOGISTS |
| US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| DK1499348T3 (en) | 2002-04-26 | 2015-01-05 | Medimmune Llc | PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE |
| CN101410519B (zh) | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| US7566458B2 (en) | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| CA2551489C (en) | 2003-12-23 | 2013-09-03 | Gregory Duke | Multi plasmid system for the production of influenza virus |
| JP4980895B2 (ja) | 2004-05-25 | 2012-07-18 | メディミューン，エルエルシー | インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体 |
| DK2497492T3 (en) | 2004-06-01 | 2018-11-26 | Icahn School Med Mount Sinai | Genetically modified swine influenza virus and its applications |
| WO2006088481A2 (en) | 2005-02-15 | 2006-08-24 | Mount Sinai School Of Medicine Of New York University | Genetically engineered equine influenza virus and uses thereof |
| EP2471552B1 (en) | 2005-03-08 | 2015-05-06 | MedImmune, LLC | Reassortant influenza viruses |
| US7790434B2 (en) | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
| EP1917352A4 (en) | 2005-06-21 | 2009-03-25 | Medimmune Vaccines Inc | METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE |
| PL2251034T3 (pl) | 2005-12-02 | 2018-07-31 | Icahn School Of Medicine At Mount Sinai | Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów |
| DK2016194T3 (en) | 2006-04-19 | 2015-06-15 | Medimmune Llc | METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS |
| WO2008133701A1 (en) | 2006-07-21 | 2008-11-06 | Medimmune, Llc. | Methods and compositions for increasing replication capacity of an influenza virus |
| CN104140958A (zh) | 2006-08-09 | 2014-11-12 | 米迪缪尼有限公司 | 流感血凝素和神经氨酸酶变体 |
| EP2674486A1 (en) | 2007-06-18 | 2013-12-18 | MedImmune, LLC | Influenza B viruses having alterations in the hemaglutinin polypeptide |
| RU2523587C2 (ru) | 2008-07-11 | 2014-07-20 | МЕДИММЬЮН, ЭлЭлСи | Варианты гемагглютинина и нейрамидазы вируса гриппа |
| EP2987856B1 (en) | 2009-02-05 | 2018-07-25 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| SG173642A1 (en) | 2009-02-12 | 2011-09-29 | Medimmune Llc | Influenza hemagglutinin and neuraminidase variants |
| WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
| DE102009024721A1 (de) | 2009-06-12 | 2010-12-16 | Erwin Bienek | Dezentrale Ladestation für batteriebetriebene Elektromobile |
| US9217157B2 (en) | 2009-07-27 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Recombinant influenza viruses and uses thereof |
| US8828406B2 (en) | 2009-07-30 | 2014-09-09 | Icahn School Of Medicine At Mount Sinai | Influenza viruses and uses thereof |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| EP4241785B1 (en) | 2011-09-20 | 2026-01-28 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| SG11201504728RA (en) | 2012-12-18 | 2015-07-30 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
| EP2968525A4 (en) | 2013-03-14 | 2016-10-26 | Icahn School Med Mount Sinai | MORBUS NEWCASTLE VIRUSES AND USES THEREOF |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| EP3110443A4 (en) | 2014-02-27 | 2017-11-15 | Viralytics Limited | Combination method for treatment of cancer |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| KR20170122786A (ko) | 2015-02-26 | 2017-11-06 | 베링거잉겔하임베트메디카게엠베하 | 2가 돼지 인플루엔자 바이러스 백신 |
| AU2016308917A1 (en) | 2015-08-20 | 2018-03-15 | Cornell University | Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus |
| US10548966B2 (en) | 2015-08-20 | 2020-02-04 | University Of Rochester | Single-cycle virus for the development of canine influenza vaccines |
| WO2017031401A2 (en) | 2015-08-20 | 2017-02-23 | University Of Rochester | Ns1 truncated virus for the development of canine influenza vaccines |
| JP2019520338A (ja) | 2016-06-03 | 2019-07-18 | ユニバーシティ オブ ロチェスター | ウマインフルエンザウイルス弱毒生ワクチン |
| MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| AR114410A1 (es) | 2018-02-27 | 2020-09-02 | Univ Rochester | Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos |
| CA3104297A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| US12350328B2 (en) | 2019-02-27 | 2025-07-08 | University Of Rochester | Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses |
| US12545718B2 (en) | 2019-04-24 | 2026-02-10 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| RU2769125C1 (ru) * | 2021-09-02 | 2022-03-28 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Генетическая конструкция для экспрессии генов mNG_CD4-CCR5, рекомбинантная плазмида rVSV_mNG_CD4-CCR5 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CCR5, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp41 ВИЧ-1 тропности R5 |
| RU2768032C1 (ru) * | 2021-09-02 | 2022-03-23 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Генетическая конструкция для экспрессии генов mNG_CD4-CXCR4, рекомбинантная плазмида rVSV_mNG_CD4-CXCR4 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CXCR4, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp 41 ВИЧ-1 тропности X4 |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
| TW202529819A (zh) | 2023-10-13 | 2025-08-01 | 美商旗艦先鋒創新公司 | 組織特異性指環載體(anellovector)遞送 |
| WO2025160409A1 (en) | 2024-01-26 | 2025-07-31 | Flagship Pioneering Innovations V, Inc. | Viral vectors for modulating vegf function |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257175T1 (de) * | 1994-07-18 | 2004-01-15 | Conzelmann Karl Klaus Prof Dr | Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus |
-
1998
- 1998-07-10 DE DE69837764T patent/DE69837764T2/de not_active Expired - Lifetime
- 1998-07-10 EP EP98933339A patent/EP1012244B1/en not_active Expired - Lifetime
- 1998-07-10 PT PT98933339T patent/PT1012244E/pt unknown
- 1998-07-10 AU AU83002/98A patent/AU731663B2/en not_active Expired
- 1998-07-10 CA CA2295858A patent/CA2295858C/en not_active Expired - Lifetime
- 1998-07-10 DK DK98933339T patent/DK1012244T3/da active
- 1998-07-10 WO PCT/US1998/014527 patent/WO1999002657A1/en not_active Ceased
- 1998-07-10 AT AT98933339T patent/ATE361973T1/de active
- 1998-07-10 JP JP2000502155A patent/JP4434478B2/ja not_active Expired - Lifetime
- 1998-07-10 ES ES98933339T patent/ES2287977T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2295858C (en) | 2011-05-10 |
| JP2003527064A (ja) | 2003-09-16 |
| AU731663B2 (en) | 2001-04-05 |
| AU8300298A (en) | 1999-02-08 |
| DE69837764D1 (de) | 2007-06-21 |
| EP1012244A4 (en) | 2004-09-15 |
| DK1012244T3 (da) | 2007-09-10 |
| PT1012244E (pt) | 2007-08-21 |
| ATE361973T1 (de) | 2007-06-15 |
| CA2295858A1 (en) | 1999-01-21 |
| JP4434478B2 (ja) | 2010-03-17 |
| ES2287977T3 (es) | 2007-12-16 |
| WO1999002657A1 (en) | 1999-01-21 |
| EP1012244B1 (en) | 2007-05-09 |
| EP1012244A1 (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69837764T2 (de) | Rhabdovirus mit gentechnisch veränderter hülle | |
| Schnell et al. | Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection | |
| DE69936577T2 (de) | Lentivirale Verpackungszellen | |
| DE68929122T2 (de) | Rekombinante Retroviren | |
| DE69830798T2 (de) | Retrovirale vektoren, die funktionelle spleiss-donor- und spleiss-akzeptor-stellen enthalten | |
| DE69838758T2 (de) | Verfahren und mittel zur herstellung von sicheren, rekombinanten lentivirusvektoren mit hohem titer | |
| DE69634904T2 (de) | Negativstrand rna virus mit selbständiger replikationsaktivität | |
| DE60035676T2 (de) | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer | |
| DE60033045T2 (de) | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten | |
| DE69131908T2 (de) | Viruspartikel mit veraendertem wirtspektrum | |
| DE69935714T2 (de) | Anti-virale vektoren | |
| DE69434724T2 (de) | Bildung, konzentration und effizienter transfer von vsv-g pseudotypisierten retroviralen vektoren | |
| DE69636248T2 (de) | Expressionssysteme | |
| EP1006196B1 (de) | Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren | |
| DE69332519T2 (de) | Defekte verpackende nicht-oncoviren vektoren aus mpmv | |
| JPH05508320A (ja) | Ｈｉｖパッケージング配列を含むベクター、パッケージング不全ｈｉｖベクター及びその使用 | |
| EP1778295A1 (de) | Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren | |
| US7081243B1 (en) | Rhabdoviruses with reengineered coats | |
| DE69529910T2 (de) | Zellen, die einen cd4-scheinrezeptor tragen und entsprechende moleküle und verfahren | |
| DE69626681T2 (de) | Konditionell-replizierende virale vektoren und ihre verwendung. | |
| WO1998038325A2 (de) | Retrovirale vektoren, verfahren zu ihrer herstellung und ihre verwendung zur genübertragung in cd4-positive zellen | |
| US7749973B2 (en) | Methods of gene transfer to astrocytes with mokola virus pseudotyped lentivirus vectors | |
| DE69426303T2 (de) | Verfahren zur unterdrückung der immunantwort durch gentherapie | |
| DE69618579T2 (de) | Rekombinante dna-vektoren für die gentherapie | |
| WO2001037881A9 (de) | Gentherapie von hiv-infizierten durch expression von membran-verankerten gp41-peptiden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |